ArchiveOctober 2009

23 post-marketing natalizumab-related PML cases

The EMEA announced, in a press-release, on the 23 October that there are now 23 post-marketing natalizumab-related PML cases: “Review of benefits and risks for Tysabri started -The Committee started a review of the benefits and risks of Tysabri, in view of reports of 23 cases of progressive multifocal leukoencephalopathy (PML) worldwide since Tysabri has been on the market. This review is...

Genetics of MS update post-ECTRIMS 2009

Studies of family members of MS patients has shown that the more closely related you are to an MS patient the higher your risk of the disease. For example, if you are a sibling or child of an MS patient your risk is about 3%. This shows that genes play a role in MS. Studies over the last 30 years has shown that a region of DNA on chromosome 6 is the main genetic locus in MS. The main gene...

Novel disease modifying therapies: data presented at ECTRIMS 2009

The 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Dusseldorf in September 2009 brought together leading international experts in MS to share and discuss recent advances in MS research. We were presented very promising new treatments evaluated in phase II and III trials. Oral therapies have reached an advanced phase of development, with some...

Panel recommends that FDA approves Fampridine for increasing walking speed in PwMS

Concerns: Aminopyridines, a family of compounds to which Fampridine belongs, works by lowering the requirements for axons (the electrical cabling of nerves) by blocking a specific group of proteins on their surface called voltage-gated potassium channels. This makes it more likely for an electrical impulse or action potential to be transmitted across a demyelinated segment of an axon. Although...

Translate

Categories

Recent Posts

Recent Comments

Archives